Puma Biotechnology, Inc. (PBYI) Stock Grade

About Puma Biotechnology, Inc.'s fundamentals

Puma Biotechnology is a modestly sized biotech company with a market capitalization of $297.6 million, trading at a P/E ratio of 9.6. The company maintains a healthy net profit margin of 13.6% and generates a strong return on equity of 23.9%, indicating efficient use of shareholder capital despite essentially flat revenue performance year-over-year at -0.9%. With no dividend payment, the company appears focused on reinvesting profits or managing cash flow rather than returning capital to shareholders. These metrics suggest a profitable operation that is generating returns for shareholders, though revenue growth remains stagnant.